Project Details
Description
Evaluate preclinical efficacy of anti alpha-synuclein antibody treatment on the onset and progression of alpha-synucleinopathy in A53T mutant human alpha-synuclein transgenic mice.
| Status | Finished |
|---|---|
| Effective start/end date | 11/7/17 → 7/31/18 |
Funding
- ABL BIO
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.